Physician profile
William Paul Coe
NPI 1972117232
$2,363.36
in general payments reported to CMS, 2019-2025
20 companies · $86.40 in 2025
The $86.40 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,023 · 2022: $105 · 2023: $808 · 2024: $341 · 2025: $86.40.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,236.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,235.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $494.86 | 2021-2024 | Farxiga, Wainua |
| Janssen Pharmaceuticals, INC | $426.12 | 2021-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $305.89 | 2021-2024 | Jardiance |
| Merck Sharp & Dohme LLC | $198.73 | 2022-2024 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $160.26 | 2021-2023 | Camzyos, Eliquis |
| Pfizer INC. | $149.34 | 2021-2024 | |
| Avanir Pharmaceuticals, INC. | $119.23 | 2021 | |
| Alnylam Pharmaceuticals INC. | $116.50 | 2023-2024 | Amvuttra, Onpattro |
| Novartis Pharmaceuticals Corporation | $94.28 | 2022-2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $88.77 | 2021 | |
| Novo Nordisk INC | $32.51 | 2025 | Wegovy |
| Esperion Therapeutics, INC. | $30.58 | 2025 | Nexletol |
| Abbvie INC. | $25.89 | 2023 | |
| Lexicon Pharmaceuticals, INC. | $24.52 | 2023 | Inpefa |
| Medtronic, INC. | $23.31 | 2025 | Linq II |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impulse Dynamics (USA) INC. | $16.43 | 2023 | Optimizer |
| Scpharmaceuticals INC. | $15.67 | 2024 | |
| Boston Scientific Corporation | $13.51 | 2024 | Watchman Access System |
| Amgen INC. | $13.49 | 2024 | Repatha |
| Inari Medical, INC. | $13.47 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Coe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.